Thymectomy in the integrated management of myasthenia gravis

Since the early days of Sauerbruch and Blalock, thymectomy has been used with increasing success in the management of myasthenia gravis. Several principles of management have emerged from this experience: the patient clearly benefits from care by a coordinated team, including a neurologist, intensivist, anesthesiologist, and surgeon in an institution familiar with the routine care of the myasthenic patient. Thymectomy is indicated early in the routine management of most patients with generalized myasthenia gravis, as well as those with purely ocular involvement uncontrolled by anticholinesterase medication. Patients should not undergo thymectomy while in crisis, but their medical condition should be optimally controlled prior to surgery, even if this requires the use of immunosuppressive agents. Because of the proven benefit in patient pain management and postoperative respiratory function, epidural adjuvant analgesia should be administered, unless contraindicated. Furthermore, the data from multiple series indicate that some form of "maximal" thymectomy should be used to try to remove all thymic tissue and induce patient clinical improvement or remission. Finally, long-term patient follow-up using an objective grading system should be maintained to optimize maximal functional status with as few medications as possible. When it is possible, there is little question that patients do better without long-term immunosuppression with steroids or other agents.